New research uncovers substantial differences in rates of childhood cancers when considering single year of age rather than grouping several years together. The study published by Wiley early online in Cancer, a peer-reviewed ...
Jun 21, 2021
0
1
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...
Apr 14, 2021
0
2
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, ...
Apr 8, 2021
0
11
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The main two subtypes are Hodgkin lymphoma and non-Hodgkin lymphoma. Because of breakthrough research, this once fatal diagnosis ...
Mar 31, 2021
0
2
Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
Mar 19, 2021
0
2
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...
Feb 18, 2021
0
12
Among patients with lymphoma admitted to the hospital for severe COVID-19, those treated with B-cell-depleting therapies within the previous 12 months had an increased risk of prolonged hospital stay and death, according ...
Feb 4, 2021
0
3
A first-of-its-kind Australian study has revealed rates of brain lymphoma have quadrupled since the 1980s with only 33% of people surviving five years after receiving a diagnosis.
Feb 2, 2021
0
1
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists ...
Dec 7, 2020
0
2
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
